Overview
Non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and disease surveillance.
Eligibility
For Cohort 1 Inclusion, the participant has/is:
- A known or suspected NSCLC treated with curative intent
- Undergone or planning to undergo a surgical resection
- 18 years old or older
- Willing and able to provide informed consent
- Willing to have additional blood samples collected during routine surveillance visits
For Cohort 2 Inclusion, the participant has/is:
- Histologically or cytologically documented Stage IV NSCLC (de novo metastatic or relapse setting) not amenable to curative surgery or radiation therapy.
- Intended to receive first line immunotherapy (as monotherapy or in combination with chemotherapy)
- Tumors that lack activating EGFR mutations and ALK fusions
- 18 years and older
- Willing and able to provide informed consent
- Willing to have additional blood samples collected during routine surveillance visits
Exclusion Criteria (both Cohorts):
- Suspected sarcoidosis, lymphoma, or metastatic cancer from other sites (i.e., those without a known or suspected NSCLC primary diagnosis)
- Not willing to have additional blood samples collected
- Patients with a secondary malignancy <2 years prior to enrollment